0.8942
3.61%
-0.0335
OptiNose Inc stock is currently priced at $0.8942, with a 24-hour trading volume of 652.84K.
It has seen a -3.61% decreased in the last 24 hours and a -48.01% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $0.9644 pivot point. If it approaches the $0.8789 support level, significant changes may occur.
OptiNose Inc Stock (OPTN) Financials Data
OptiNose Inc (OPTN) Revenue 2024
OPTN reported a revenue (TTM) of $70.99 million for the quarter ending December 31, 2023, a -6.93% decline year-over-year.
OptiNose Inc (OPTN) Net Income 2024
OPTN net income (TTM) was -$35.48 million for the quarter ending December 31, 2023, a +52.59% increase year-over-year.
OptiNose Inc (OPTN) Cash Flow 2024
OPTN recorded a free cash flow (TTM) of -$20.86 million for the quarter ending December 31, 2023, a +69.19% increase year-over-year.
OptiNose Inc (OPTN) Earnings per Share 2024
OPTN earnings per share (TTM) was -$0.32 for the quarter ending December 31, 2023, a +64.04% growth year-over-year.
OptiNose Inc Stock (OPTN) Latest News
Optinose to Present at the Needham Virtual Healthcare Conference
GlobeNewswire Inc.
XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps
GlobeNewswire Inc.
OptiNose (OPTN) Reports Q4 Loss, Lags Revenue Estimates
Zacks Investment Research
Optinose Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights
GlobeNewswire Inc.
Optinose Announces Reporting Date for Fourth Quarter 2023 Financial Results
GlobeNewswire Inc.
Zevra Therapeutics (ZVRA) Soars 6.6%: Is Further Upside Left in the Stock?
Zacks Investment Research
About OptiNose Inc
OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States. The company offers XHANCE, a therapeutic product utilizing its proprietary optinose exhalation delivery system that delivers a topically-acting and potent anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps. It also markets Onzetra Xsail (AVP-825) for the acute treatment of migraines in adults through its license agreement with Avanir Pharmaceuticals, Inc. In addition, the company is developing XHANCE for the treatment of chronic sinusitis; OPN-300 for the treatment of Prader-Willi syndrome, a rare genetic obesity disorder, as well as autism spectrum disorder; and OPN-021 for the treatment of narcolepsy or Parkinson diseases. Further, it is involved in developing antibiotics, anticholinergics, antihistamines, mucolytics, leukotriene inhibitors, and other medication classes. OptiNose, Inc. was founded in 2010 and is headquartered in Yardley, Pennsylvania.
Cap:
|
Volume (24h):